INDP — Indaptus Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.15
+$0.02 (+1.33%)
Indaptus Therapeutics Inc (INDP) is a biotechnology company listed on NASDAQ. It is led by Jeffrey A. Meckler J.D., based in Three Columbus Circle, New York, NY, United States, 10019, with about 7 employees. Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Net income was -$3.0M. INDP currently screens at market cap $7.4M.
On the latest cached filing, INDP: AND EXCHANGE COMMISSION (8-K 2026-09-01). This INDP stock page is the analysis view: what changed in the numbers, and why it matters for Indaptus Therapeutics Inc.
Use this INDP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INDP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INDP SEC filings page. Lician reads the product cache first so this HTML stays unique to Indaptus Therapeutics Inc even when a live quote feed is slow.
What changed in INDP
8-K · 2026-09-01
INDP: AND EXCHANGE COMMISSION
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
INDP Key Statistics
Market Cap
$7.37M
Volume
343,234
Previous Close
$1.16
Day Range
$1.13 – $1.18
EPS
-$1.61
Revenue
$0.00
Net Income
-$15.02M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
7
INDP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$15.02M | -$15.42M | -$14.32M | -$7.71M |
| EPS (Diluted) | -$1.61 | -$1.83 | -$1.73 | $0.00 |
Total Assets
$7.34M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.79M
Operating Cash Flow
-$12.32M
Free Cash Flow
$0.00
Indaptus Therapeutics Inc Company Information
- CEO & Director
- Jeffrey A. Meckler J.D.
- Headquarters
- Three Columbus Circle, New York, NY, United States, 10019
- Website
- indaptusrx.com
- Phone
- 646 427 2727
- IPO / Founded
- 2015-08-04
- Sector
- Healthcare
- Industry
- Biotechnology